- Home
- INM vs SNPX Comparison
INM vs SNPX Comparison
Compare INM & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- SNPX
- Stock Information
- Founded
- INM 1981
- SNPX 2012
- Country
- INM Canada
- SNPX United States
- Employees
- INM N/A
- SNPX N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- INM Health Care
- SNPX Health Care
- Exchange
- INM Nasdaq
- SNPX Nasdaq
- Market Cap
- INM 3.2M
- SNPX 3.1M
- IPO Year
- INM N/A
- SNPX N/A
- Fundamental
- Price
- INM $3.33
- SNPX $4.64
- Analyst Decision
- INM
- SNPX Strong Buy
- Analyst Count
- INM 0
- SNPX 1
- Target Price
- INM N/A
- SNPX N/A
- AVG Volume (30 Days)
- INM 9.5M
- SNPX 2.7M
- Earning Date
- INM 05-12-2025
- SNPX 08-13-2025
- Dividend Yield
- INM N/A
- SNPX N/A
- EPS Growth
- INM N/A
- SNPX N/A
- EPS
- INM N/A
- SNPX N/A
- Revenue
- INM $4,920,990.00
- SNPX N/A
- Revenue This Year
- INM N/A
- SNPX N/A
- Revenue Next Year
- INM N/A
- SNPX N/A
- P/E Ratio
- INM N/A
- SNPX N/A
- Revenue Growth
- INM N/A
- SNPX N/A
- 52 Week Low
- INM $1.72
- SNPX $1.84
- 52 Week High
- INM $15.70
- SNPX $6.19
- Technical
- Relative Strength Index (RSI)
- INM 59.24
- SNPX 63.57
- Support Level
- INM $2.26
- SNPX $3.25
- Resistance Level
- INM $5.50
- SNPX $4.44
- Average True Range (ATR)
- INM 0.40
- SNPX 0.87
- MACD
- INM 0.11
- SNPX 0.04
- Stochastic Oscillator
- INM 37.04
- SNPX 80.22
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.